M&T Bank Corp Buys 231,620 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

M&T Bank Corp increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 2,569.6% during the fourth quarter, Holdings Channel.com reports. The firm owned 240,634 shares of the biotechnology company’s stock after purchasing an additional 231,620 shares during the quarter. M&T Bank Corp’s holdings in Arrowhead Pharmaceuticals were worth $15,976,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in Arrowhead Pharmaceuticals by 3.3% in the 3rd quarter. Vanguard Group Inc. now owns 16,035,870 shares of the biotechnology company’s stock worth $553,077,000 after purchasing an additional 510,798 shares during the period. Avoro Capital Advisors LLC raised its holdings in Arrowhead Pharmaceuticals by 2.8% in the 3rd quarter. Avoro Capital Advisors LLC now owns 10,900,000 shares of the biotechnology company’s stock worth $375,941,000 after purchasing an additional 300,000 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in Arrowhead Pharmaceuticals by 3,142.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company’s stock worth $71,797,000 after purchasing an additional 2,017,489 shares during the period. Goldman Sachs Group Inc. raised its holdings in Arrowhead Pharmaceuticals by 34.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock worth $22,189,000 after purchasing an additional 447,456 shares during the period. Finally, Baker BROS. Advisors LP raised its holdings in Arrowhead Pharmaceuticals by 77.9% in the 3rd quarter. Baker BROS. Advisors LP now owns 1,670,762 shares of the biotechnology company’s stock worth $57,625,000 after purchasing an additional 731,588 shares during the period. 62.61% of the stock is owned by institutional investors.

Insider Activity

In other news, insider James C. Hamilton sold 10,000 shares of Arrowhead Pharmaceuticals stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $64.19, for a total value of $641,900.00. Following the sale, the insider directly owned 236,958 shares of the company’s stock, valued at approximately $15,210,334.02. The trade was a 4.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 3.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, March 25th. Morgan Stanley upgraded shares of Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $78.00 to $100.00 in a research note on Tuesday. Weiss Ratings upgraded shares of Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Friday, February 6th. Chardan Capital raised their target price on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Finally, B. Riley Financial raised their price target on Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, Arrowhead Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $83.78.

Arrowhead Pharmaceuticals Trading Up 0.6%

Shares of ARWR stock opened at $74.40 on Friday. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $12.44 and a 12-month high of $76.76. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.29. The stock’s 50-day moving average price is $62.63 and its 200-day moving average price is $57.95. The stock has a market capitalization of $10.42 billion, a price-to-earnings ratio of 48.63 and a beta of 1.26.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The firm had revenue of $264.03 million during the quarter, compared to the consensus estimate of $225.66 million. During the same period last year, the firm posted ($1.39) earnings per share. The company’s revenue for the quarter was up 10461.3% compared to the same quarter last year. Equities research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -3.37 EPS for the current fiscal year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.